"Immunotherapy, Adoptive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
| Descriptor ID |
D016219
|
| MeSH Number(s) |
E02.095.465.425.400.330.050.400 E05.478.550.520.050.400
|
| Concept/Terms |
Immunotherapy, Adoptive- Immunotherapy, Adoptive
- Immunotherapy, Adoptive Cellular
- Adoptive Immunotherapy
- Adoptive Immunotherapies
- Immunotherapies, Adoptive
- Cellular Immunotherapy, Adoptive
- Adoptive Cellular Immunotherapies
- Cellular Immunotherapies, Adoptive
- Immunotherapies, Adoptive Cellular
- Adoptive Cellular Immunotherapy
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy, Adoptive".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy, Adoptive".
This graph shows the total number of publications written about "Immunotherapy, Adoptive" by people in this website by year, and whether "Immunotherapy, Adoptive" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 3 | 3 |
| 2003 | 2 | 4 | 6 |
| 2004 | 2 | 4 | 6 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 2 | 3 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 2 | 3 |
| 2010 | 4 | 2 | 6 |
| 2011 | 1 | 1 | 2 |
| 2012 | 3 | 2 | 5 |
| 2013 | 5 | 0 | 5 |
| 2014 | 3 | 1 | 4 |
| 2015 | 4 | 2 | 6 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 6 | 1 | 7 |
| 2019 | 6 | 2 | 8 |
| 2020 | 5 | 1 | 6 |
| 2021 | 15 | 2 | 17 |
| 2022 | 2 | 14 | 16 |
| 2023 | 2 | 12 | 14 |
| 2024 | 15 | 8 | 23 |
| 2025 | 27 | 5 | 32 |
| 2026 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy, Adoptive" by people in Profiles.
-
Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma. Blood Adv. 2026 Feb 24; 10(4):1023-1034.
-
New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma. Blood Adv. 2026 Jan 13; 10(1):217-227.
-
Tuning CAR-T cells by targeting cancer-associated glycan in pancreatic cancer. Nat Commun. 2025 Dec 10; 16(1):11246.
-
Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis. Blood Adv. 2025 Nov 11; 9(21):5654-5662.
-
In vivo CRISPR screens identify modifiers of CAR T cell function in myeloma. Nature. 2025 Oct; 646(8086):953-962.
-
Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL. Blood Adv. 2025 Sep 09; 9(17):4405-4414.
-
Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement. Blood Adv. 2025 Aug 26; 9(16):4081-4089.
-
Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study. Blood Adv. 2025 Aug 12; 9(15):3694-3705.
-
Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: A CIBMTR Analysis. Transplant Cell Ther. 2025 Dec; 31(12):1000.e1-1000.e11.
-
Secretion of a VEGF-Blocking scFv Enhances CAR T-cell Potency. Cancer Immunol Res. 2025 Aug 01; 13(8):1132-1144.